用 mRNA 电穿孔的 HBV-TCR T 细胞治疗 HBV-HCC

StephenW

用 mRNA 电穿孔的 HBV-TCR T 细胞治疗 HBV-HCC
安东尼 T 谭 1 , 安东尼奥贝托莱蒂 1 2
隶属关系
隶属关系

    1
    新发传染病，杜克-新加坡国立大学医学院，新加坡。
    2
    新加坡免疫学网络，新加坡科技局 (A∗STAR)。

    PMID：35919490 PMCID：PMC9327102 DOI：10.1093/immadv/ltab026

抽象的

肝细胞癌是一项重大的全球健康挑战，东亚地区的发病率稳步上升。虽然丙型肝炎和乙型肝炎病毒感染占 HCC 病例的大部分，但针对 HCV 感染的强效抗病毒药物的出现使病因学偏向于慢性 HBV 感染，目前仍没有有效的治愈方法。因此，HBV-HCC 仍然是一个持续存在的全球性问题。 HBV-HCC 中晚期的治疗选择仍然有限，因此需要新的治疗策略来满足这一医疗需求。随着针对 B 细胞恶性肿瘤的过继性 T 细胞免疫疗法取得相当大的成功，可以想象是否也可以针对 HBV-HCC 实现同样的效果。在这篇综述中，我们描述了针对 HBV-HCC 的 T 细胞治疗策略的发展，并讨论了这些策略在直接杀死肿瘤细胞和可能由 T 细胞作用引起的其他改变方面的安全性和有效性.

关键词：T细胞免疫治疗；乙型肝炎；肝细胞癌;肿瘤微环境。

© 作者 2021。牛津大学出版社代表英国免疫学会出版。

StephenW

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
Anthony T Tan  1 , Antonio Bertoletti  1   2
Affiliations
Affiliations

    1
    Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
    2
    Singapore Immunology Network, Agency for Science and Technology (A∗STAR), Singapore.

    PMID: 35919490 PMCID: PMC9327102 DOI: 10.1093/immadv/ltab026

Abstract

Hepatocellular carcinoma is a significant global health challenge with steadily increasing incidence in the East Asia region. While both Hepatitis C and B virus infections account for the majority of HCC cases, the advent of potent antivirals against HCV infection has biased the aetiology towards chronic HBV infection that at the moment remains without an effective cure. For this reason, HBV-HCC remains a persistent global problem. Treatment options for intermediate to advanced stages of HBV-HCC remain limited, hence novel therapeutic strategies are required to fulfil this medical need. Following the considerable success of adoptive T-cell immunotherapy against B-cell malignancies, it is conceivable to envision whether the same could be achieved against HBV-HCC. In this review, we describe the development of T-cell therapy strategies for HBV-HCC and discuss the safety and the efficacy of the strategies in terms of the direct killing of tumour cells and the other alterations possibly induced by the action of the T cells.

Keywords: T-cell immunotherapy; hepatitis B; hepatocellular carcinoma; tumour microenvironment.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.

StephenW

https://academic.oup.com/immunot ... 2360679/ltab026.pdf